公开(公告)号：EP3626741A1

公开(公告)日：2020-03-25

申请号：EP19196212.5

申请日：2014-02-20

申请人： The Trustees of The University of Pennsylvania ,  University of Pittsburgh - Of the Commonwealth System of Higher Education ,  Novartis AG

发明人： BROGDON, Jennifer ,  LOEW, Andreas ,  JOHNSON, Laura Alexandra ,  JUNE, Carl H. ,  MAUS, Marcela ,  SCHOLLER, John ,  OKADA, Hideho

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K38/00 ,  A61P35/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

公开(公告)号：EP2958943B1

公开(公告)日：2019-09-11

申请号：EP14713280.7

申请日：2014-02-20

申请人： The Trustees of The University of Pennsylvania ,  University of Pittsburgh - Of the Commonwealth System of Higher Education ,  Novartis AG

发明人： BROGDON, Jennifer ,  LOEW, Andreas ,  JOHNSON, Laura Alexandra ,  JUNE, Carl H. ,  MAUS, Marcela ,  SCHOLLER, John ,  OKADA, Hideho

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K38/00 ,  A61P35/00

公开(公告)号：EP2958943A1

公开(公告)日：2015-12-30

申请号：EP14713280.7

申请日：2014-02-20

申请人： The Trustees of The University of Pennsylvania ,  University of Pittsburgh - Of the Commonwealth System of Higher Education ,  Novartis AG

发明人： BROGDON, Jennifer ,  LOEW, Andreas ,  JOHNSON, Laura Alexandra ,  JUNE, Carl H. ,  MAUS, Marcela ,  SCHOLLER, John ,  OKADA, Hideho

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K38/00 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

摘要翻译： 本发明提供用于治疗与EGFRvIII表达相关的疾病的组合物和方法。 本发明还涉及对EGFRvIII特异性的嵌合抗原受体（CAR），编码它的载体和包含抗-EGFRVIII CAR的重组T细胞。 本发明还包括施用表达CAR的遗传修饰的T细胞的方法，其包含抗EGFRvIII结合结构域。

公开(公告)号：EP2608799A2

公开(公告)日：2013-07-03

申请号：EP11820530.1

申请日：2011-08-23

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： OKADA, Hideho

IPC分类号： A61K38/08 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K9/0019 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/2086 ,  A61K39/39 ,  A61K2039/5154 ,  A61K2039/55566 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/70 ,  C07K14/4703 ,  C07K14/4705 ,  C07K14/705 ,  C07K14/7155 ,  A61K2300/00

摘要： Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

公开(公告)号：EP2207874B1

公开(公告)日：2014-12-03

申请号：EP08836827.9

申请日：2008-10-08

申请人： Intrexon Corporation ,  University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： BRAUGHLER, J., Mark ,  KUMAR, Prasanna ,  STORKUS, Walter, J. ,  OKADA, Hideho

IPC分类号： C12N5/00 ,  C12N5/02 ,  C12N15/00

CPC分类号： A61K35/15 ,  A61K31/00 ,  A61K31/166 ,  A61K31/4245 ,  A61K38/00 ,  A61K45/06 ,  C07K14/5434 ,  C07K2319/715 ,  C12N5/0639 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2510/00 ,  C12N2710/10343 ,  C12N2830/002 ,  C12N2840/203 ,  G01N33/6866 ,  G01N2333/57 ,  G01N2800/52 ,  A61K2300/00

摘要： This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL- 12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

公开(公告)号：EP2608799B1

公开(公告)日：2018-12-12

申请号：EP11820530.1

申请日：2011-08-23

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： OKADA, Hideho

IPC分类号： A61K38/08 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K9/0019 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/2086 ,  A61K39/39 ,  A61K2039/5154 ,  A61K2039/55566 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/70 ,  C07K14/4703 ,  C07K14/4705 ,  C07K14/705 ,  C07K14/7155 ,  A61K2300/00

摘要： Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.